Not an official event of the 2018 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or the Conquer Cancer Foundation.

This activity is supported by educational grants from Bristol-Myers Squibb Company, Eisai Inc and Genentech BioOncology.

Agenda

Meeting Format and Agenda

This unique activity will feature several distinct content modules during which the faculty will review available data sets, present cases from their practices and provide perspectives on key clinical questions as part of a moderated discussion. The event will not include traditional didactic lectures, and the following topics will be reviewed.

Spectrum of toxicities and rates of discontinuation observed with atezolizumab/bevacizumab versus sunitinib in IMmotion151

Potential role of atezolizumab/bevacizumab in the management of mRCC

Early activity and safety observed with the use of anti-PD-1/PD-L1 antibodies in combination with VEGF-directed tyrosine kinase inhibitors (eg, avelumab/axitinib, pembrolizumab/lenvatinib, pembrolizumab/axitinib)

FDA breakthrough therapy designations for avelumab/axitinib and pembrolizumab/lenvatinib; implications for the development of time lines and ongoing research

Appreciate the recent FDA approval of nivolumab in combination with ipilimumab as front-line treatment for intermediate- and poor-risk advanced RCC, and develop strategies to optimally integrate these agents into the clinical care of patients.

Recognize toxicities attributable to diverse systemic treatments for RCC, and offer preventive or emergent interventions to minimize or ameliorate these side effects.

Appraise emerging clinical trial data evaluating anti-PD-1/PD-L1 antibodies in combination with other immunotherapeutic or targeted agents for previously untreated or relapsed metastatic RCC, and prepare for the potential availability of these approaches in routine practice.

Recall available and emerging data with other investigational agents and strategies currently in testing for RCC and, where applicable, refer eligible patients for trial participation or other expanded access programs.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Location

Directions:
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center.

Registration

Thank you for your interest in our educational program. At this time, online preregistration is closed. However, seats are still available for the conference. Onsite registration will be open starting at 6:15 AM (Central Time) on Monday, June 4th. If you are interested in attending, please visit our registration desk in the Grand Ballroom foyer located on the second level of the Hilton Chicago (720 Michigan Avenue, Chicago, IL).

Please note, onsite registrant seating will be prioritized for healthcare professionals directly involved in the treatment of patients. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.